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Carcinoembriogenic antigen (CEA) is a serum marker 
commonly used as a clinical tool in the follow-up of 
patients with several types of tumor, particularly colorectal 
carcinoma. An elevation in CEA levels can precede clinical 
evidence of recurrence, but these levels can also increase 
in patients with nonmalignant pathologies. Nevertheless, 
an elevation in CEA levels is always associated with 
the introduction of extensive work-ups and typically 
generates significant patient anxiety. Orlistat is a medication 
commonly used as an adjunctive weight-control measure 
due to its ability to decrease the absorption of dietary 
triglycerides. Its predominant side-effects are related to its 
activity in the gastrointestinal tract. We report the case of a 
patient who developed a documented, reversible elevation 
in CEA with the use of this medication. The use of orlistat 
should be considered in the differential diagnosis of patients 
presenting unexplained elevations of CEA. 
CASE REPORT
A 66-year-old female patient was submitted to a left 
hemicolectomy in January 2002 due to a T3N0M0 well-
differentiated colon adenocarcinoma. At that time, no 
adjuvant treatment was recommended for the patient. One 
year later, during a routine follow-up examination, the 
patient was found to have elevated levels of CEA and a chest 
X-ray showing a 1.5-cm nodule in the right upper lung lobe. 
A CAT scan confirmed the presence of this nodule, which 
was consistent with a metastatic lesion. The patient was 
treated with capecitabine as a single agent, which resulted 
in partial remission. A resection of the lung nodule was 
carried out in August 2003, and the pathologic examination 
confirmed the presence of a metastatic adenocarcinoma 
consistent with the primary colon cancer. 
The patient remained free of any signs of recurrent 
disease, with a normal CEA (normal value < 5.0 ng/dl) 
level, for several years after the aforementioned treatment. 
However, in January 2008, after having taken orlistat (120 
mg, three times per day) for weight control for 6 months, the 
patient was found to have an elevated CEA level of 8.3 ng/
dl (baseline 3.0 ng/dl). The test was repeated, and this result 
was confirmed. A thorough work-up, including a laboratory 
evaluation of renal, liver and thyroid function, as well as 
a positron emission tomography and a colonoscopy, were 
carried out and showed no abnormalities. Four weeks later a 
reanalysis of the patient’s CEA level confirmed an elevated 
CEA level of similar magnitude.
In August 2008 the patient was advised to discontinue 
the use of orlistat. In September the patient’s CEA level had 
returned to the normal range. The measurement was repeated 
monthly and has remained normal ever since, with the most 
recent test completed in January 2009, with a result of 3.1 
ng/dl. 
INTRODUCTION
CEA was first described as a colon cancer marker in 
19651. Since that time, CEA has been demonstrated to be 
a valuable clinical tool in the follow-up of patients with 
colorectal carcinoma2. Elevated levels of CEA can precede 
clinical evidence of tumor recurrence in up to 80% of 
patients, underscoring its usefulness in the management 
of colorectal cancer patients. It is well known that CEA 
is an immunoglobulin-like protein produced in the 
gastrointestinal mucosa whose level can increase in other 
malignant and nonmalignant pathologies. Therefore, in spite 646
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of its clear clinical utility, CEA is not as specific as initially 
hypothesized. Consequently, the correct interpretation of 
elevated CEA levels requires a careful clinical investigation 
to identify the reason for this abnormality. 
Because of its low specificity, serum CEA levels should 
not be used for colon cancer screening3. Normal CEA values 
are between 2.5 ng/ml and 3.0 ng/ml for non-smokers and 
between 2.5 ng/ml and 5.0 ng/ml for smokers4.
Orlistat is widely used as an adjunct weight-control 
measure due to its ability to decrease the absorption of 
dietary triglycerides by inhibiting intestinal lipases. The 
predominant side-effects of orlistat are gastrointestinal 
in nature, including intestinal borborygmi, abdominal 
cramps, flatus, fecal incontinence, oily spotting and flatus 
with discharge.5 In a meta-analysis of nine clinical trials, 
these side-effects occurred in 15 to 30 percent of patients6. 
Less frequently, orlistat can induce moderate and adverse 
gastrointestinal effects, such as abdominal pain. A few cases 
of serious hepatic adverse effects (cholelithiasis, cholostatic 
hepatitis and subacute liver failure) have also been reported.7 
DISCUSSION 
In this case report, a patient with an elevated level of 
CEA was identified during a routine follow-up examination. 
Interestingly, the CEA level returned to the normal range 
when orlistat use was discontinued. We hypothesized that 
such an observation could possibly be attributed to enteritis 
due to the presence of fatty stool in the bowel, the same 
explanation for the majority of orlistat’s adverse effects. 
To our knowledge, this is the first report to link the 
use of orlistat to the development of elevated CEA levels. 
Considering the number of patients who use this medication 
for weight control, it may be an important cause of false-
positive CEA elevations. Based on this clinical observation, 
we believe that inquiring about the use of orlistat should 
be part of the evaluation of patients who present with 
unexplained elevations of CEA. 
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